International private equity firm Cinven and Chicago-based Linden Capital Partners (‘Linden’) announce that Cinven has agreed to make a strategic investment in Regenity Biosciences (‘Regenity’ or ‘the Company’), a global developer and manufacturer of bioresorbable technologies and Linden portfolio company. Founded in 1997 and headquartered in New Jersey, USA, Regenity has spent nearly 30 years advancing innovative biomaterials that support the body’s natural healing processes for tissue and bone regeneration across multiple clinical areas. Today, the Company’s team of over 250 employees serves more than 125 customers with 80+ product lines globally.
Read the full article: Regenity Biosciences Receives Strategic Investment from Cinven, Adding New Partner Alongside Linden Capital Partners //
Source: https://www.cinven.com/news-insights/regenity-biosciences-announcement/